Navigation Links
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Date:5/10/2013

s and withdrawals due to pruritus than the vehicle treated patients.

Eliot Forster , CEO of Creabilis, said: "We are excited by the results seen in this Phase 2b trial. In particular, the benefits of CT327 in treating pruritus are very encouraging and take us closer to the market in an indication with no currently available treatments. We anticipate further clinical development activity, targeting pruritus, in the near term. CT327 will represent a breakthrough for patients and doctors alike, both of whom currently struggle to deal with this distressing condition."  

David Roblin , CMO of Creabilis, said: "Pruritus is a debilitating yet under-recognised symptom in psoriasis and in other dermatological and systemic diseases. It has a significant impact on patients' quality of life and is currently poorly treated. There are no licensed products available, nor an established standard of care. There is a significant unmet need for a targeted treatment of chronic pruritus that combines efficacy with a good safety profile. In this study, up to 77% of CT327 treated patients had no or mild pruritus by the end of therapy. Combined with its outstanding safety profile, CT327 has the potential to provide a great benefit to patients."

About the Trial

The trial was a randomised, double-blind placebo controlled dose finding study of the efficacy and safety of a CT327 ointment at 0.05%, 0.1% and 0.5% w/w administered twice daily for eight weeks. One hundred and sixty patients with mild to moderate psoriasis were recruited. The study endpoints were IGA (Investigator Global Assessment), pruritus (VAS), mPASI and adverse event reports. Full data are expected to be presented at a scientific meeting later in 2013.

About Creabilis SA

Creabilis is a late clinical stage European biotechnology company with corporate and R&D functions spread across the UK and Italy
'/>"/>

SOURCE Creabilis SA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
2. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
3. Allscripts announces first quarter 2013 results
4. The MED Group Announces New Agreement with CareCentrix Effective May 1, 2013
5. ASSA ABLOY Door Group Announces RF Shielding Openings
6. APHY announces new store openings as part of major expansion
7. NxStage Announces Second Quarter 2013 Investor Conference Schedule
8. Pro-Dex, Inc. Announces Fiscal 2013 Third Quarter Financial Results Conference Call and Webcast
9. Parametrics Medical, LLC Announces the Release of Their Coll-e-Strong Line of Soft Tissue Allografts
10. Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
11. GW Pharmaceuticals plc Announces the Closing of its Initial Public Offering on the Nasdaq Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Dec. 11 As Warner Chilcott plc (Nasdaq: ... global branded prescription pharmaceuticals business of The Procter & ... Acquisition"), constituted a change of control under a global ... P&G subsidiary acquired by Warner Chilcott and Sanofi-Aventis U.S. ...
... , IRVINE, Calif., Dec. 11 PRO-DEX, INC. (Nasdaq: ... Annual Shareholders Meeting held on December 4, 2009. At the ... Healey, David Holder and Mark Murphy as directors; (ii) approved the ... split if it should elect to do so at any time ...
Cached Medicine Technology:Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 2Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 3Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 4Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4
(Date:7/13/2014)... published today in The Lancet Neurology ... the long term neurological problems that repeated concussions ... common form of sports-related traumatic brain injury (TBI), ... include dementia, amyotrophic lateral sclerosis, and other neurological ... perhaps more concerning, is that even when the ...
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... 13, 2014 The North American water storage ... 2013 to $5,450 million by 2018, at a CAGR of ... is expanding at a rapid pace in North America. The ... laws on water & wastewater storage and collection, and the ... market is expanding at a healthy rate in Canada, and ...
(Date:7/13/2014)... According to a new market ... by Component (processor, GPU, DSP, connectivity), Technology Node ... Geography - Forecast and Analysis to 2014-2020", published ... Computing Market is expected to reach $61.70 Billion ... from 2014 to 2020. , Browse 71 market ...
(Date:7/13/2014)... July 13, 2014 Athletes with a ... period from concussions, according to research presented today at ... ) Annual Meeting. The research marks the first of ... on the known physical events that occur after a ... a long allele in the (GT)n genotype were four ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... March Issue of Nicotine and Tobacco Research Analyzes Trends, ... date, the majority of research conducted about tobacco use ... heavy smoking. The March 2009 issue of ... light and intermittent smoking. Several of the nation,s preeminent ...
... Dr. Matt Regulski --FORT WORTH, Texas, March 20 ... Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), ... 09 on March 19-21, 2009 at the Renaissance ... considered the premier international multidisciplinary diabetic foot conference ...
... DICK GEPHARDT SERVES ON MMR INFORMATION SYSTEMS, ... MMR Information Systems, Inc. (OTC Bulletin ... subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") provides consumer-controlled ... and electronic safe deposit box storage solutions ...
... well, study says there,s no rush to abandon standard care ... of maggots to treat leg ulcers is similar to standard ... to British researchers. , Debridement (removal of dead tissue ... common part of treatment for leg ulcers, chronic wounds most ...
... SOUTH EASTON, Mass., March 20 Pressure BioSciences, Inc. ... today provided an update on various corporate activities, including ... Innovation Research ("SBIR") Grant from the National Institutes of ... of the Harvard School of Public Health ...
... Nasdaq: SHPGY ), the global specialty biopharmaceutical ... (39) lots of the ADHD patch DAYTRANA (the lots ... below). Shire is taking this action because some ... specification, and as a result, patients and caregivers could ...
Cached Medicine News:Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 2Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 3Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 4Health News:Wound Management Technologies Exhibits at Premier International Diabetic Foot Conference DFCon 09 2Health News:Wound Management Technologies Exhibits at Premier International Diabetic Foot Conference DFCon 09 3Health News:Former House Democratic Leader Richard A. Gephardt to Join MMR Initiative to Promote Immediate Use of Personal Health Records 2Health News:Former House Democratic Leader Richard A. Gephardt to Join MMR Initiative to Promote Immediate Use of Personal Health Records 3Health News:Former House Democratic Leader Richard A. Gephardt to Join MMR Initiative to Promote Immediate Use of Personal Health Records 4Health News:Maggots as Good as Gel in Leg Ulcer Treatments 2Health News:Pressure BioSciences, Inc. Provides Corporate Update 2Health News:Pressure BioSciences, Inc. Provides Corporate Update 3Health News:Pressure BioSciences, Inc. Provides Corporate Update 4Health News:Pressure BioSciences, Inc. Provides Corporate Update 5Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 2Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 3Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 4Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 5
Inquire...
Inquire...
... The Micro MB for Microhematocrit meets or ... the NCCLS "Standard Procedure for the Determination ... Method" as well as other U.S. and ... Microhematocrit determinations, order Cat. No. 3411 or ...
... two centrifuges -- the world's most popular ... in one reliable, quiet, compact unit. It ... two separate centrifuges!, For your microcentrifuge needs, ... supplies you with the MicroMB centrifuge, microcentrifuge ...
Medicine Products: